Washington, D.C.-based gene therapy outfit Regenxbio just raised $30 million to bring its platform into the clinic.
The dollars will help Regenxbio generate clinical proof of concept data, as well as work toward in-licensing new programs. The company’s also using the money to beef up its clinical and manufacturing processes, it said in a statement.
Regenxbio has developed what it calls NAV Technology – a form of adeno-associated viral gene therapy that treats lysosomal storage disorders and ocular disease. It’s got drugs in the pipeline that treat Hurler syndrome, Hunter syndrome, wet age-related macular degeneration and X-linked retinitis pigmentosa.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Here’s how it works: In Hurler syndrome, for instance, children don’t carry a gene that develops an enzyme called IDUA that breaks down complex sugars. These build up, and ultimately impair mental development, organ function, physical abilities and appearance. The NAV platform delivers a normal copy of the IDUA-producing gene – which ultimately embeds itself into a patient’s DNA in a one-time doze so that patients can produce the enzyme. The research comes out of the University of Pennsylvania, and has been successful in vivo – so it’s a matter of testing its efficacy in a real patient pool.
The company’s also out-licensing this technology for other indications, with companies like Baxter, Dimension Therapeutics and Lysogene developing viral vector-based gene therapy for a number of other indications.
The Series C funding was led by Venrock and Brookside Capital, with other investors like Deerfield Management, FoxKiser and Fidelity Biosciences.